Product Reports Resources Pricing Login Book a demo

Basilea Pharmaceutica

Biotech & Life Sciences · Allschwil, Switzerland · Founded 2000 · IPO 2004

Commercial stage biopharmaceutical company MoreLess

Basilea Pharmaceutica is a biopharmaceutical company based in Basel, Switzerland, and listed on the SIX Swiss Exchange under the ticker SIX BSLN. The company specializes in the research, development, and commercialization of innovative anti-infective treatments. Its core products, Cresemba and Zevtera, are aimed at addressing severe bacterial and fungal infections. Basilea primarily serves healthcare providers, hospitals, and clinics worldwide, focusing on markets with high unmet medical needs in infectious diseases. The company operates on a business model that combines in-house research and development with strategic partnerships and licensing agreements to bring its products to market. Revenue is generated through product sales, royalties, and milestone payments from partners.

Keywords: biopharmaceutical, anti-infective, Cresemba, Zevtera, healthcare, hospitals, clinics, research, development, commercialization.

Valuation $524M
Revenue $241M
EBITDA $65M
Total funding $100–500M
Power Law Thoroughbred$100M+ revenue

Talent graph

Basilea Pharmaceutica's talent

Book a demo to see the people
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on Basilea Pharmaceutica's cap table

Sourced from Dealroom's funding and investor records.

Seed 2 investors entered at this stage
US Biomedical Advanced Research and Development Authority
CARB-X
Series B+ 1 investor entered at this stage
Athyrium Capital Management

Global footprint

Where Basilea Pharmaceutica has talent and traffic

Workforce by country
12 countries with
team presence
🇨🇭 Switzerland81%
🇫🇷 France8%
🇩🇪 Germany2.9%
🇨🇳 China2.2%
🇮🇹 Italy0.7%
Top 5 of 12 shown
Web traffic by country
8.6K monthly visits
across markets
🇨🇭 Switzerland29.1%
🇺🇸 United States29.1%
🇩🇪 Germany18.6%
🇫🇷 France15.1%
🇬🇧 United Kingdom15.1%
Top 5 markets shown

Patent intelligence

$26M patent portfolio · 25 active families

Estimated portfolio value
$26M
4.9% of market cap · 2.4× smaller than top peer COMPASS Pathways ($63M)
25 active patent families
Where Basilea Pharmaceutica innovates Amino radicalArylCephalosporinCombinatorial chemistryDisease

Where Basilea Pharmaceutica concentrates vs peers

Each axis is a top-10 topic across Basilea Pharmaceutica and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Basilea Pharmaceutica

An AI-synthesized read of the highest-engagement posts about Basilea Pharmaceutica on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Basilea Pharmaceutica on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles